Galliapharm 0.74-1.85 GBq radionuklidigeneraattori Finsko - finština - Fimea (Suomen lääkevirasto)

galliapharm 0.74-1.85 gbq radionuklidigeneraattori

eckert & ziegler radiopharma gmbh - gallium (68ga) chloride, germanium (68ge) chloride - radionuklidigeneraattori - 0.74-1.85 gbq - muut diagnostiset radioaktiiviset lÄÄkevalmisteet

Tanonalla 5 mg / 2.5 mg depottabletti Finsko - finština - Fimea (Suomen lääkevirasto)

tanonalla 5 mg / 2.5 mg depottabletti

sandoz a/s - oxycodone hydrochloride, naloxone hydrochloride dihydrate - depottabletti - 5 mg / 2.5 mg - oksikodoni ja naloksoni

Tanonalla 10 mg / 5 mg depottabletti Finsko - finština - Fimea (Suomen lääkevirasto)

tanonalla 10 mg / 5 mg depottabletti

sandoz a/s - oxycodone hydrochloride, naloxone hydrochloride dihydrate - depottabletti - 10 mg / 5 mg - oksikodoni ja naloksoni

Tanonalla 20 mg / 10 mg depottabletti Finsko - finština - Fimea (Suomen lääkevirasto)

tanonalla 20 mg / 10 mg depottabletti

sandoz a/s - oxycodone hydrochloride, naloxone hydrochloride dihydrate - depottabletti - 20 mg / 10 mg - oksikodoni ja naloksoni

Tanonalla 30 mg / 15 mg depottabletti Finsko - finština - Fimea (Suomen lääkevirasto)

tanonalla 30 mg / 15 mg depottabletti

sandoz a/s - oxycodone hydrochloride, naloxone hydrochloride dihydrate - depottabletti - 30 mg / 15 mg - oksikodoni ja naloksoni

Tanonalla 40 mg / 20 mg depottabletti Finsko - finština - Fimea (Suomen lääkevirasto)

tanonalla 40 mg / 20 mg depottabletti

sandoz a/s - oxycodone hydrochloride, naloxone hydrochloride dihydrate - depottabletti - 40 mg / 20 mg - oksikodoni ja naloksoni

ALPHA JECT 3000 injektioneste, emulsio Finsko - finština - Fimea (Suomen lääkevirasto)

alpha ject 3000 injektioneste, emulsio

pharmaq as - aeromonas salmonicida var salmonicida -bacteria, inactivated, listonella anquillarum, serotype 02a, inactivated, listonella anguillarum, serotype 01, inactivated - injektioneste, emulsio

SomaKit TOC Evropská unie - finština - EMA (European Medicines Agency)

somakit toc

advanced accelerator applications - edotreotide - neuroendocrine tumors; radionuclide imaging - diagnostiset radiofarmaseuttiset valmisteet - tämä lääkevalmiste on tarkoitettu vain diagnostiseen käyttöön. kun radioaktiiviseen merkitsemiseen, jossa gallium - (68ga) kloridi ratkaisu, ratkaisu gallium (68ga) edotreotide saatu on tarkoitettu positroniemissiotomografia (pet) kuvantaminen somatostatiini-reseptorien yliekspressio aikuisille potilaille, joilla on todettu tai epäillään hyvin eriytetty maha-enteropancreatic neuroendokriinisiä kasvaimet (gep-net) paikallistamisen ensisijainen kasvaimia ja niiden etäpesäkkeitä.

GALLIUM CITRATE GA-67 37 MBq/ml injektioneste, liuos Finsko - finština - Fimea (Suomen lääkevirasto)

gallium citrate ga-67 37 mbq/ml injektioneste, liuos

ge healthcare limited - gallii (67ga) citras - injektioneste, liuos - 37 mbq/ml - gallium(67ga)sitraatti

Blincyto Evropská unie - finština - EMA (European Medicines Agency)

blincyto

amgen europe b.v. - blinatumomab - prekursorisolujen lymfoblastinen leukemia-lymfooma - antineoplastiset aineet - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.